Blue Water Acquisition — Clarus Therapeutics Holdings — Investor Presentation (January 2022)
27 slides from Blue Water Acquisition's investor presentation, Jan 19, 2022
Slide 1: Investor Presentation January 2022
androgen & metabolic therapies for better health Investor Presentation January 2022 Exhibit 99.1
Slide 2: Forward-looking statements
Certain statements in this presentation constitute “forward-looking statements” for purposes of the federal securities laws. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,”
Slide 3: Investment Summary
Challenges we're anticipating Build a product accessible on all devices JATENZO® is the first & only FDA-approved oral softgel for testosterone replacement therapy (TRT) in appropriate adult men TRT is an attractive & growing market JATENZO has strong intellectual property protection: Worldwide pate
Slide 4: Meet Our Leadership Team
DR. ROBERT DUDLEY President & Chief Executive Officer RIC PETERSON Chief Financial Officer Meet Our Leadership Team STEVE BOURNE Chief Administrative Officer DR. JAY NEWMARK Chief Medical Officer JAMES HOLLOWAY SVP, Manufacturing & Supply FRANK JAEGER Chief Commercial Officer DR. ZHANNA JUMADILOVA C
Slide 5: The JATENZO Opportunity
NOC 69087-158-12 NOC 69087-237-12 JATENZO’ & JATENZO’ é (eststerone undecanoate) (testosterone undecanoate) sules nsules RX on, clarug R 20 Soft Gelatin Capsules mmruns 2 x Only a Soft Gelatin capsules mmrunset The JATENZO Opportunity clarus THERAPEUTICS @@™
Slide 6: Growing Opportunity
8.1MM TRX/YR2 ~2.2MM treated ~6MM diagnosed ~20MM affected 1. U.S. Census (2019); Int J of Clin Pract (2006); J Clin Endo Metabolism (2007); Symphony Healthcare (2014); IMS Health (2015); StrataMark survey results. 2. Data Sources: Symphony Metys Data January 2021 through December 2021. Growing Oppo
Slide 7: JATENZO is First Oral T Softgel Approved by FDA
Convenient *As demonstrated in JATENZO Phase 3 “inTUne” trial; see product labeling and J Clin Endocrinol Metab 105: 1-17, 2020. Effective* Safe* easy-to-swallow softgel taken twice daily (BID) with food dose adjustable option 87% of men achieved T levels in normal range restored T levels to mid-nor
Slide 8: Current non-oral TRT treatments pose challenges for patients
Current non-oral TRT treatments pose challenges for patients TRT Cycle of Discontinuation 1. On behalf of Clarus Therapeutics, Inc., Harris Poll conducted online survey between May 6 – June 5, 2020. 2. Data from Symphony PTD Rx claims from January 2021 to December 2021. Included approved claims only
Slide 9: Beneficial Clinical Attributes of JATENZO
Beneficial Clinical Attributes of JATENZO References: Swerdloff, RS and Dudley, RE. Ther Adv Urol 2020; 12: 1-16. Swerdloff, RS, et al. J Clin Endocrinol Metab 2020:105: 1-17. Increases free T & improves classic symptoms associated with hypogonadism
Slide 10: JATENZO Safety Profile
Most common adverse events (AEs) were: headache (4.8%), increased hematocrit (4.8%), hypertension (3.6%), decreased HDL cholesterol (3.0%), & nausea (2.4%)*, 1 JATENZO not associated with:2 Liver toxicity Prostate disease Adverse changes in CV risk biomarkers [hs-CRP, LpPLA2, Lp(a)] Clinically signi
Slide 11: Maximizing JATENZO's Commercial Potential
Maximizing JATENZO's Commercial Potential
Slide 12: Poised to Accelerate JATENZO Growth
60 Clinical Sales Specialists cover ~80% of TRT market prescriptions Poised to Accelerate JATENZO Growth PCPs, UROs, & ENDOs targeting top deciles HCP education & patient advertising drive awareness Corporate Account Directors focused on expanding payer coverage NOTE: Data from Symphony PTD Rx claim
Slide 13: DTC is Key to Drive JATENZO Demand
dtc is key DTC is Key to Drive JATENZO Demand Patient awareness Direct-to-consumer advertising Patient demand i-- i--
Slide 14: Competitive & Affordable Coverage
Competitive & Affordable Coverage *Data sources: Competitive data using MMIT (as of 8/26/2021) Payer Coverage Across All Channels* * Payer channels include Commercial, Medicare Part D, Medicaid, & Health Exchanges Payers reimburse brands
Slide 15: Sales Force Expansion
Sales Force Expansion Flexibility to expand sales force for greater reach & frequency based on JATENZO performance Increasing HCP awareness
Slide 16: Patient-focused HUB Supports Journey
from beginning . . . . . . . . . . . .. . . . . to JATENZO in patient’s hands Patient-focused "HUB" Supports Journey
Slide 17: HUB Designed to Drive JATENZO Demand
Find-a-Doc Targeted HCPs Clarus expanded sales force increases reach & frequency Directly ships to patient Patient HUB service Patient sees JATENZO DTC Patient visits JATENZO website Telemedicine HUB Designed to Drive JATENZO Demand Patient easily reorders JATENZO Patient satisfied
Slide 18: Growth Opportunities
Growth Opportunities |
Slide 19: 3-Part Growth Strategy
3-Part Growth Strategy JATENZO Life-Cycle Management Once-Daily - hypogonadism (8.1MM TRx/yr) F-T-M transgender (700K males)1 Chronic Kidney Disease (>2MM hypogonadal men)2 CLAR-121 (Testosterone + Anastrozole) Inflammatory breast disease; breast cancer* CLAR-222 (CoQ10 + Caspofungin) Primary & seco
Slide 20: CLAR-121 (Testosterone + Anastrozole)
CLAR-121 (Testosterone + Anastrozole) Proprietary asset for certain forms of breast disease/breast cancer MOA: activates AR-dependent anti-inflammatory mechanism(s) in breast tissue Painful, debilitating inflammation of breast tissue (L) No effective pharmaceutical intervention; often results in dis
Slide 21: CLAR-222 (CoQ10 + Caspofungin)
dtc is key CLAR -222 (CoQ10* + Caspofungin) In-licensed from McGill University Worldwide IP & marketing rights Upfront, success-based milestones & royalty payments CoQ10 is natural coenzyme vital for mitochondrial function; caspofungin is FDA-approved antifungal drug Extensive preclinical proof-of-c
Slide 22: Pipeline of Assets & Timelines
Pipeline of Assets & Timelines R&D Program Description Clinical Development Phase Projected Initiation JATENZO: CKD Treatment of hypogonadal men with chronic kidney disease* Phase 4** 1H 2022 Once daily (QD) oral TU Treatment of male hypogonadism Phase 2 2H 2022 JATENZO: male transgender T therapy f
Slide 23: Strong IP & Exclusivity Pathways
Strong IP & Exclusivity Pathways CLAR-121 & CLAR-222 Clear pathway to issued IP & market exclusivity Patent applications pending in U.S. & major non-U.S. pharma markets Potential five-year Hatch-Waxman market exclusivity upon FDA approval Potential seven-year orphan drug market exclusivity upon FDA
Slide 24: Financial Highlights
My HoLDIng \ oe Financial Highlights arus THERAPEUTICS «Se
Slide 25: Financial Highlights
Financial Highlights Revenue $9.4MM Gross profit margin 84.8% Operating expenses $40.4MM Outstanding shares 9.2MM Current cash & cash equivalents $22.0MM For the 9 months ended 9/30/21
Slide 26: Key Takeaways
Key Takeaways Experienced leadership team has extensive, relevant backgrounds & exceptional track record commercializing innovative therapies in our target markets JATENZO: is first-in-class FDA-approved oral softgel for attractive & growing TRT market has labeling expansion opportunities has patent
Slide 27: androgen & metabolic therapies for better health
androgen & metabolic therapies for better health Investor Presentation January 2022
Clarus Therapeutics Holdings — Investor Presentation (January 2022) on 6ix